Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters

The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological advances, other innovative biologics, such as...

Celý popis

Podrobná bibliografie

Hlavní autoři:	HoUng Kim, Rieke Alten, Fraser Cummings, Silvio Danese, Geert D’Haens, Paul Emery, Subrata Ghosh, Cyrielle Gilletta de Saint Joseph, JongHyuk Lee, James O. Lindsay, Elena Nikiphorou, Ben Parker, Stefan Schreiber, Steven Simoens, Rene Westhovens, Ji Hoon Jeong, Laurent Peyrin-Biroulet
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2021-01-01
Edice:	mAbs
Témata:	Biobetter biologic biosimilar CT-P13 infliximab innovative biologics
On-line přístup:	https://www.tandfonline.com/doi/10.1080/19420862.2020.1868078
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!